ABCL
AbCellera Biologics Inc.
$5.24
+8.71%
2026-05-08
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Key Fundamentals
Forward P/E
-5.92
EPS (TTM)
$-0.49
ROE
-14.5%
Revenue Growth (YoY)
788.2%
Profit Margin
-194.9%
Debt/Equity
14.81
Price/Book
1.54
Beta
1.03
Market Cap
$1.51B
Avg Volume (10D)
10.2M
Recent Breakout Signals
No recent breakout signals detected for ABCL.
Recent Price Range (60 Days)
60D High
$5.25
60D Low
$2.93
Avg Volume
4.5M
Latest Close
$5.24
Get breakout alerts for ABCL
Sign up for Breakout Scanner to receive daily notifications when ABCL triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
AbCellera Biologics Inc. (ABCL) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ABCL daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ABCL operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.